Tofacitinib for the treatment of refractory or glucocorticoid-dependent cutaneous leukocytoclastic vasculitis

Dermatol Ther. 2022 Nov;35(11):e15780. doi: 10.1111/dth.15780. Epub 2022 Aug 29.

Authors

Jinlu Ma¹, Wentian Lu¹, Dong Yan¹, Zhichun Liu¹, Leixi Xue¹

Affiliation

¹ Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

PMID: 35988047
DOI: 10.1111/dth.15780

No abstract available

Publication types

Letter

MeSH terms

Glucocorticoids / adverse effects
Humans
Piperidines / adverse effects
Skin Diseases, Vascular*
Vasculitis, Leukocytoclastic, Cutaneous* / chemically induced
Vasculitis, Leukocytoclastic, Cutaneous* / diagnosis
Vasculitis, Leukocytoclastic, Cutaneous* / drug therapy

Substances

Glucocorticoids
tofacitinib
Piperidines